{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:06:31Z","timestamp":1792076791020,"version":"4.4.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":285,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:p>\n                    Sofosbuvir (Sovaldi, SOF) is a nucleotide analog prodrug that targets the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase and inhibits viral replication. High sustained virological response rates are achieved when SOF is used in combination with ribavirin with or without pegylated interferon in subjects with chronic HCV infection. Potential mechanisms of HCV resistance to SOF and other nucleos(t)ide analog NS5B polymerase inhibitors are not well understood. SOF was the first U.S. Food and Drug Administration (FDA)\u2010approved antiviral drug for which genotypic resistance analyses were based almost entirely on next\u2010generation sequencing (NGS), an emerging technology that lacks a standard data analysis pipeline. The FDA Division of Antiviral Products developed an NGS analysis pipeline and performed independent analyses of NGS data from five SOF clinical trials. Additionally, structural bioinformatics approaches were used to characterize potential resistance\u2010associated substitutions. Using protocols we developed, independent analyses of the NGS data reproduced results that were comparable to those reported by Gilead Sciences, Inc. Low\u2010frequency, treatment\u2010emergent substitutions occurring at conserved NS5B amino acid positions in subjects who experienced virological failure were also noted and further evaluated. The NS5B substitutions, L159F (sometimes in combination with L320F or C316N) and V321A, emerged in 2.2%\u20104.4% of subjects who failed SOF treatment across clinical trials. Moreover, baseline polymorphisms at position 316 were potentially associated with reduced response rates in HCV genotype 1b subjects. Analyses of these variants modeled in NS5B crystal structures indicated that all four substitutions could feasibly affect SOF anti\u2010HCV activity.\n                    <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>\n                    : SOF has a high barrier to resistance; however, low\u2010frequency NS5B substitutions associated with treatment failure were identified that may contribute to resistance of this important drug for chronic HCV infection. (H\n                    <jats:sc>epatology<\/jats:sc>\n                    2015;61:56\u201365)\n                  <\/jats:p>","DOI":"10.1002\/hep.27375","type":"journal-article","created":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T13:03:25Z","timestamp":1408021405000},"page":"56-65","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":157,"title":["Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir"],"prefix":"10.1097","volume":"61","author":[{"given":"Eric F.","family":"Donaldson","sequence":"first","affiliation":[{"name":"Division of Antiviral Products,U.S. Food and Drug Administration,Silver Spring,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Harrington","sequence":"additional","affiliation":[{"name":"Division of Antiviral Products,U.S. Food and Drug Administration,Silver Spring,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian J.","family":"O'Rear","sequence":"additional","affiliation":[{"name":"Division of Antiviral Products,U.S. Food and Drug Administration,Silver Spring,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Naeger","sequence":"additional","affiliation":[{"name":"Division of Antiviral Products,U.S. Food and Drug Administration,Silver Spring,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2014,11,20]]},"reference":[{"key":"hep27375-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"hep27375-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"hep27375-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1128\/JVI.01980-09","article-title":"1a\/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus","volume":"84","year":"2010","journal-title":"J Virol"},{"key":"hep27375-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1128\/JVI.00386-12","article-title":"Structure of hepatitis C virus polymerase in complex with primer\u2010template RNA","volume":"86","year":"2012","journal-title":"J Virol"},{"key":"hep27375-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI\u20107977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"hep27375-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low\u2010level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","year":"2014","journal-title":"J Infect Dis"},{"key":"hep27375-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"12334","DOI":"10.1128\/JVI.05639-11","article-title":"Hepatitis C virus nucleotide inhibitors PSI\u2010352938 and PSI\u2010353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA","volume":"85","year":"2011","journal-title":"J Virol"},{"key":"hep27375-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1093\/bioinformatics\/bts605","article-title":"Tools for mapping high\u2010throughput sequencing data","volume":"28","year":"2012","journal-title":"Bioinformatics"},{"key":"hep27375-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/infdis\/170.5.1157","article-title":"Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy","volume":"170","year":"1994","journal-title":"J Infect Dis"},{"key":"hep27375-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1128\/AAC.34.3.436","article-title":"Susceptibilities of zidovudine\u2010susceptible and \u2010resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay","volume":"34","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"hep27375-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.10.011","article-title":"Resistance of human cytomegalovirus to ganciclovir\/valganciclovir: a comprehensive review of putative resistance pathways","volume":"101","year":"2014","journal-title":"Antiviral Res"},{"key":"hep27375-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/hep.25581","article-title":"Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS\u2010790052","volume":"55","year":"2012","journal-title":"Hepatology"},{"key":"hep27375-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/jac\/dks234","article-title":"Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays","volume":"67","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"hep27375-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"15517","DOI":"10.1074\/jbc.M808889200","article-title":"Slow binding inhibition and mechanism of resistance of non\u2010nucleoside polymerase inhibitors of hepatitis C virus","volume":"284","year":"2009","journal-title":"J Biol Chem"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.27375","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201501000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T20:58:21Z","timestamp":1729198701000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201501000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,20]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.27375","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,20]]},"assertion":[{"value":"2014-05-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}